Payment overview · 2025
General Payments
$318.15
21 reported records · 7 companies
Healthcare provider profile · identity verified
Regina Kaur, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, KY · NPI 1881121077
Verified facts
What the public records show
CMS Open Payments records show Regina Kaur, MD received $318.15 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.10 | 44.4% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $66.77 | 21.0% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $48.40 | 15.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.79 | 5.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.35 | 4.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.26 | 4.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $13.48 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.15 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.85 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.35 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $66.77 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $48.40 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.25 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 147 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 139 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 39 |
| Gabapentin | Gabapentin | 80 | 25 |
| Losartan Potassium | Losartan Potassium | 80 | 22 |
| Montelukast Sodium | Montelukast Sodium | 78 | 17 |
| Metformin Hcl | Metformin Hcl | 75 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 19 |
| Lisinopril | Lisinopril | 59 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 25 |
| Ozempic | Semaglutide | 50 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 14 |
| Trazodone Hcl | Trazodone Hcl | 42 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Omeprazole | Omeprazole | 37 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 18 |
| Allopurinol | Allopurinol | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Famotidine | Famotidine | 31 | 13 |
| Furosemide | Furosemide | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | 12 |
| Buspirone Hcl | Buspirone Hcl | 21 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Anastrozole | Anastrozole | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Jardiance | Empagliflozin | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.15 · 21 records | Novo Nordisk Inc | CREON, IBSRELA, LEQVIO, LINZESS, Ozempic, REZDIFFRA, Rybelsus, VYEPTI, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error